## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket Number:

CARR-0084 (103216.00252)

In re the Application of:

Yawei Ni, et al.

Serial No.:

10/059,627

Filed:

January 29, 2002

Art Unix

1654

Examiner:

Michael V. Meller

For:

COMBINATION OF A GROWTH FACTOR AND A PROTEASE

**ENZYME** 

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450 CERTIFICATE OF MAILING: I hereby certify that this correspondence is addressed to Commissioner for Patents, P. O. Box 1450, Alexandra, VA 22313is being deposited with the United States Postal Service on

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Herewith is Form PTO-1449 together with one copy of each document listed thereon. Please note also any item(s) designated below:

> The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, which ever event occurs last 37 C.F.R. § 1.97(b).

X

The fee set forth in 37 CFR 1.17(p) \$180.00 is enclosed.

Each document listed on enclosed Form PTO-1449 was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this correspondence.

X

Respectfully submitted,

07/03/2006 HGUTEMA1 00000039 10059627

01 FC:1806

180.00 OP

T. Ling Chwang Reg. No. 33,590

June

Jackson Walker L.L.P. 901 Main Street, Suite 6000 Dallas, Texas 75202

Phone: (214) 953-5959 Fax: (214) 661-6870

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/059,627	
Filing Date	January 29, 2002	
First Named Inventor	Yawei Ni, et al.	
Art Unit	1654	
Examiner Name	Michael V. Meller	
Attorney Docket Number	CARR-0084 (103216.00252)	

U. S. PATENT DOCUMENTS						
Examiner Cite Initials* No.		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2 (f known)</sup> US-	<del>- </del>		3	
		05-			l	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	-	US-				
		US-				
		US-				
		US-			,	
L		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	†	US-				

Examiner Cite No.1	Cite No.1	Date	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
			MM-DD-YYYY			Т
	1	EP 0 307 847 A2	03/22/1989	Kakkar, et al.	Entire Document	
	2	EP 0 619 370 A1	10/12/1994	Pierce, et al.	Entire Document	
						L
	!					-
			<del></del>			₽

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Doc#:	4300918
-------	---------

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO & TRADOMER'S				e required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Cubbina				Application Number	10/059,627	
INFO	DRMATION	DIS	CLOSURE	Filing Date	January 29, 2002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Yawei Ni, et al.	
(Use as many sheets as necessary)				Art Unit	1654	
(Use as many sneeds as necessary)			ecessary)	Examiner Name	Michael V. Meller	
Sheet	2	of	2	Attorney Docket Number	CARR-0084 (103216.00252)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	3	PUTNINS EE, Firth JD, Uitto VJ. Keratinocyte growth factor stimulation of gelatinase (matrix metalloproteinase-9) and plasminogen activator in histiotypic epithelial cell culture. (Abstract). J Invest Dermatol. 1995 Jun;104(6):989-94.	
	4	TSUBOI R, Sato C, Kurita Y, Ron D, Rubin JS, Ogawa H. Keratinocyte growth factor (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. (Abstract). J Invest Dermatol. 1993 Jul;101(1):49-53.	
	5	WERNER S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev. 1998 Jun;9(2):153-65.	
	6	Preliminary Notice of Rejection from the Taiwan Patent Office. Dated April 26, 2006.	
	7	Preliminary Notice of Rejection from the Taiwan Patent Office (Translated to English). Dated April 26, 2006.	
<u> </u>			

Examiner	Date		
Signature	 Considered	_	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Doc No.:

4295140

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.